Comparative study of tamsulosin versus tadalafil in benign prostatic hyperplasia patients with lower urinary tract symptoms. A prospective randomized study
Urology Annals · 2022-01 · 14 (3) · 236-240
DOI: 10.4103/ua.ua_6_21 ↗Kurz gefasst
Fachartikel in der Zeitschrift Urology Annals, 2022-01. Verfasst von Malik Suhail Ahmad und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, SKIMS, Srinagar, Jammu and Kashmir, India. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
Benign prostatic hyperplasia (BPH) is one of the common causes of lower urinary tract symptoms (LUTS) in aging men. Men with LUTS have a higher incidence of erectile dysfunction (ED), and LUTS themselves represent an independent risk factor for ED, triggering a significant negative impact on quality of life. Materials and Methods: A total of 92 patients were randomly assigned to two groups. Groups I and II had 45 and 47 patients, two patients from Group I and three patients from Group II did not follow and were excluded from the study. Patients in Group I received 0.4 mg of tamsulosin and Group II patients received 5 mg tadalafil. Patients were assessed at baseline, 3 months, and at 6 months after receiving treatment. Treatment efficacy was measured by a change in Qmax, post void residual urine (PVR), International Prostate Symptom Score (IPSS), and Sexual Health Inventory for Men (SHIM) score at 3 months and 6 months.
Results
Baseline parameters between the two groups were similar. Mean Qmax improved by 7 ml/s at 3 months to 9.44 ml/s at 6 months in Group I versus 4.73 ml/s at 3 months to 6.46 ml/s at 6 months in Group II ( P = 0.739). Mean PVRU decreased by 35.53 ml at 3 months to 47.23 ml at 6 months in Group I versus 44.98 at 3 months to 58.28 ml at 6 months in Group II ( P = 0.102). IPSS score improved by 4.24 points at 3 months to 7.22 points at 6 months in Group I versus 4 points at 3 months to 5.02 points at 6 months in Group II ( P = 0.336). SHIM score improved by 0.7 points 16.2 at 3 months to 0.8 points at 6 months in Group I versus 6.12 points at 3 months to 6.3 points at 6 months ( P < 0.001).
Conclusion
When both groups were compared, tadalafil showed statistically similar improvements in Qmax, PVRU, and IPSS score, but statistically significant improvement was observed with tadalafil in SHIM score compared with tamsulosin in treating LUTS secondary to BPH. Our study provides evidence that once daily tadalafil 5 mg is well tolerated and can be considered for the treatment of LUTS secondary to BPH especially in patient with ED.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, SKIMS, Srinagar, Jammu and Kashmir, India.
Zitieren
APA
Ahmad, M. S., Dar, Y. A., Khawaja, A. R., Para, S. A., Malik, S. A., Wani, M. S., Bhat, A. H., & Wani, P. M. (2022). Comparative study of tamsulosin versus tadalafil in benign prostatic hyperplasia patients with lower urinary tract symptoms. A prospective randomized study. Urology Annals, 14(3), 236-240. https://doi.org/10.4103/ua.ua_6_21
Vancouver
Ahmad MS, Dar YA, Khawaja AR, Para SA, Malik SA, Wani MS, et al. Comparative study of tamsulosin versus tadalafil in benign prostatic hyperplasia patients with lower urinary tract symptoms. A prospective randomized study. Urology Annals. 2022;14(3):236-240. doi:10.4103/ua.ua_6_21
BibTeX
@article{Ahmad2022,
author = {Ahmad, Malik Suhail and Dar, Yaser Ahmad and Khawaja, Abdul Rauf and Para, Sajad Ahamd and Malik, Sajad Ahamad and Wani, Mohammad Saleem and Bhat, Arif Hamid and Wani, Prince Muzaffar},
title = {Comparative study of tamsulosin versus tadalafil in benign prostatic hyperplasia patients with lower urinary tract symptoms. A prospective randomized study},
journal = {Urology Annals},
year = {2022},
volume = {14},
number = {3},
pages = {236--240},
doi = {10.4103/ua.ua_6_21}
}
EUVIMED